2:08 PM
 | 
Aug 08, 2018
 |  BC Extra  |  Politics & Policy

Rep. Collins indicted with insider trading in biotech shares

A grand jury charged Rep. Christopher Collins (R-N.Y.) Wednesday with insider trading in shares of Australian biotech Innate Immunotherapeutics Ltd. (ASX:IIL) by alerting family members of a clinical trial failure before the results were made public.

According to the indictment filed with the U.S. District Court for the Southern District of New York, Collins was a member of Innate's board and held about 16.8% of the company's stock at the time of the alleged offense. On June 22, 2017, Innate's CEO sent an email alerting board members that the company's sole candidate, MIS416, had failed in...

Read the full 465 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >